Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of SAL0120 Tablets in Patients With Chronic Kidney Disease (CKD).

NCT07716618 is registered in ClinicalTrials.gov with Shenzhen Salubris Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07716618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07716618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of SAL0120 Tablets in Patients With Chronic Kidney Disease (CKD).
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 17, 2025
Completion date
August 31, 2026
Enrollment
320 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease